Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes most definitely. $ONCS EP+IL12 induces autologous TCells and more IL12s gneration inside the hot tumors converted from being a cold tumors and hence the 57% BORR rate going on +18 months with the Keytruda Combo. IMO Dan's job is much easier than the ADXS case
Yes most definitely. Unfortunately none of the ADXS trials, so far as I can find, have proven high efficacy.
In addition, again as far as I can find, ADXS remains the sponsor for the Phase 3 trial so that they may be footing the main costs of the trial whereas the BP is the Collaborator or maybe just the advisor with their expertise. This could account for the high cash drain on ADXS and their COH. JMHO
However ADXS PPS is now $3 having reached $16 in 2016 and $30 in 2015
Elite has been taken off-line again
Yes most definitely. $ONCS has a very strong pipeline with proven safety and efficacy clinical results. Dan O'Connor's expertise combined with $ONCS EP+IL12 tech should be able to bring BP Partners onboard. Dan will certainly have earned Shareholders respect if he can take $ONCS PPS into the double digits. IMO $ONCS $10, $20, and even $30 PPS are all reachable in 2017/2018
In one year's time $ONCS shareholders will vote on whether to award Dan O'Connor the 2 mil shares. Dan has to earn it.
Agree totally. Just need more Patience. Dan has a big incentive to prove his worth as a Partnership negotiator.
Absolutely very dangerous to buy any biotech on Margin.
AMGN being a BP took a chance with ADXS.
Any preclinical trials are especially risky and $ONCS Dr. Pierce and others would need to convince any BP that a Partnership risk is worth it with Humans for a Phase1A.
If one has a Margin Call then the Broker has the legal right to sell their client's shares to cover the loss.
New CEO Dan is making things happening by talking to BP for Partnerships. Dan did this with several Partners for ADXS for each of their clinical Trials.
Dan O'Connor smart negotiations as ADXS CEO in partnership with Amgen strategy in play here for $ONCS Partnership?
http://www.amgen.com/media/news-releases/2016/08/amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration/
That is correct. Shares in a margin account can be used by the broker to lease out for Shorting.
That is good Cat Whisperer. When $VCEL's CEO and Lawyer Nick Dominick Colangelo said it then IMO the odds are very high that it all happens sometime between now, any day, and Dec 31, 2017!
Working with lawyers on Patents is a completely different section of lawyering vs working with lawyers on International and domestic contracts. Both cases are highly detailed with respect to tying in the technology and legal details.
Cat Whisperer, when we do International licensing contracts etc, waiting and receiving the monies involved being transferred to the USA, then it has given all parties involved the opportunity to resolve and agree on all terms of the Contract including persons involved, the manufacturing details, the place in Country involved (China), the confidentiality of the technology(FDA Approved BLAs), the supervision by the principals (VCEL) etc. So essentials all terms are agreed involved with lawyers from both sides legalizing all the details.
It is the formal approval by the Chinese CFDA and gov't regulatory officials authorities to approve the complete licensing contract between $VCEL and ICT.
Yes it is much more than licensing. ICT has build brand new facilities in China where the MACI BLA will be manufactured under $VCEL supervision.
For those of us in the Pharma Industry, $VCEL licensing deal such as with ICT is a Partnership.
It is all the signs IMO of Institutions reaping the $VCEL cheap shares. This pattern has been repeated at least 4 times in the last 3 months. $VCEL has $36 mil COH after they collect the receivables of past Epicel and MACI surgeries. The ICT Partnership formalization is expected to be PRed in the next 5 weeks based on CC comments.
$VCEL HOD = $4.40
Thxs to $ELTP for having a superb 55,000 sq ft GMP facility
Yes they do.
Looking good
$ELTP 55,000 sq ft facilities looking great.
$ELTP Photos update
http://www.elitepharma.com/our-facility/
Can you find out what biotechs are in the list.
Yes most definitely the Pharma industry accepts a higher PE for high growth period. After the high growth is over, the PE will settle down into the 20 range.
Indeed yes. With expected growth the MKT will assess a higher PE ratio of at least PE=30 for a Pharma. I have seen such higher PEs for Pharmas. Here are two examples.
REGN PE=35
MRK PE=52
Peter Hoang has become a very active CEO for $TPIV.
If we look at NFLX at $1.96 per sh, it has a very high PE=196 and an EPS of $1.00. IMO I am thinking that with MACI sales accelerating and new users such as the US Army signing MACI contracts, the MKT will be at least thinking that a $VCEL with PE=40 is reasonable for 2018.
Most definitely IMO also. $VCEL double digits coming.
$VCEL B/A $3.90/$3.95 Wake up retail investors Institutionals are acquiring the $VCEL Cheapie shares
Gremlin3a This is what we have been waiting for.
IMO ICT is that partner in $VCEL MACI both in China and USA.
$VCEL amazing growth going on with new hires.
sharkey1 Yes it does . The FDA keeps taking Elite off-line and then putting Elite back on-line
Absolutely YES.
$ELTP EPS is -$0.01 vs EGLT pathetic whopping loss EPS is -$3.39
That would be a miracle saving $thousands for each patient, IF that would be the case. So do the BPs recognize the potential of $ONCS new treatment to induce autologous cancer removal with an off-shelf therapy over and above EP+IL2 combo Keytruda healing of 57% BORR???